Why 7-OH tablets are being called "gas station oxy"

At a glance: 7-OH tablets vs. prescription opioids

Key Takeaways

• The "gas station oxy" nickname reflects pharmacology, not hype. Concentrated 7-OH binds the same mu-opioid receptors as oxycodone and produces the same category of effects.
• The FDA issued warning letters to companies selling concentrated 7-OH products in 2025, describing 7-OH as a "novel potent opioid" that cannot lawfully be sold as a dietary supplement or food ingredient.
• The FDA specifically named 7Tabz Retail, LLC in a June 25, 2025 warning letter. A second wave of seven warning letters followed in July 2025, targeting additional companies.
• Johnson County, Kansas medical examiners reported six 7-OH-related overdose deaths in a six-week period in 2026. The DEA filed notices of intent for temporary Schedule I placement in July 2026.
• "Sold at a store" is a distribution fact, not a safety endorsement. Products that are easy to buy can still cause serious harm or death.

Why the comparison to oxycodone

The comparison is not rhetorical. It is mechanistic.

Oxycodone works by binding to mu-opioid receptors in the brain and spinal cord, producing pain relief, sedation, and euphoria. 7-OH works through the same pathway. The FDA's 2025 scientific assessment confirmed that 7-OH is a potent mu-opioid receptor agonist with pharmacological properties consistent with classical opioids like morphine and fentanyl. Preclinical studies have shown 7-OH produces respiratory depression with more than three times the potency of morphine; receptor binding studies suggest its affinity at the mu-opioid receptor exceeds morphine's, though the precise multiplier varies across assay methods.

People who use concentrated 7-OH tablets describe effects that closely mirror what they know from prescription opioids: a warm, sedating high that fades and pulls them back for more. This is not a coincidence. It is the expected effect of a potent opioid agonist.

The dependence curve also mirrors prescription opioids. Tolerance can develop within days to weeks of regular use. Once physical dependence is established, stopping produces withdrawal: muscle aches, sweating, anxiety, insomnia, and cravings. This is the other half of the "oxy" comparison, and it is what keeps people coming back even when they want to stop.

What are Press'd, 7Tabz, and the other 7-OH tablet products?

The concentrated 7-OH tablet market emerged as the kratom industry shifted from raw leaf powder to high-potency extracts. Products in this category contain 7-OH at concentrations far above what occurs naturally in the kratom plant. In the natural leaf, 7-OH is present only in trace amounts. Concentrated tablet products can contain 7-OH at levels many times higher, in some cases near-pure concentrations, which is what the FDA's enforcement actions targeted.

Brands like Press'd and 7Tabz are examples of the concentrated-tablet product category that regulators and clinicians are warning about. The FDA issued a warning letter to 7Tabz Retail, LLC on June 25, 2025, calling its 7-OH products unapproved new drugs. Press'd is a widely distributed brand selling tablets in doses ranging from 18mg to 300mg of 7-OH, available at retailers across the country. These and similar products are sold without a prescription, without pharmacy oversight, and without standardized manufacturing controls.

Several features of the category make it particularly difficult for consumers to assess risk:

Why "legal and over the counter" does not mean safe

This is the belief that makes 7-OH tablets dangerous beyond their pharmacology: many people who buy them assume the gas station shelf is a proxy for regulatory approval.

It is not. The FDA has stated that concentrated 7-OH products cannot lawfully be sold as dietary supplements or food ingredients because they do not meet the legal standards for either category. Products in this market exist in a regulatory gap, not in a safety-verified space. The FDA's enforcement actions, which began in June 2025, targeted this gap directly.

The FDA issued a warning letter to Hydroxie, LLC that flagged adverse event reports linking 7-OH products to liver toxicity, seizures, respiratory depression, and deaths. A second round of seven warning letters in July 2025 targeted additional companies, including Shaman Botanicals, My Smoke Wholesale, Thang Botanicals, Royal Diamond Imports, and others.

The real-world toll supports the regulatory concern. Johnson County, Kansas's chief medical examiner reported six 7-OH-related overdose deaths in a six-week period leading up to July 2026, with one additional death recorded in 2025. Medical examiners in multiple counties have documented fatal overdoses involving concentrated 7-OH, often in combination with alcohol or other central nervous system depressants. Regulators in Florida, Louisiana, Kansas, and other states have moved to restrict or ban concentrated 7-OH products, and the DEA filed notices of intent for temporary federal Schedule I placement in July 2026.

Naloxone reverses 7-OH overdose, but because 7-OH has a longer half-life than naloxone, a person may appear to recover and then relapse into respiratory depression as the naloxone wears off. Hospital monitoring after apparent recovery is essential.

Signs it has become a problem

Concentrated 7-OH use can transition to dependence faster than most people expect, for the same reason any potent opioid agonist drives dependence: tolerance builds quickly, and the absence of the drug produces withdrawal that feels like a physical emergency.

Signs that use has moved beyond occasional:

• Needing more tablets to feel the same effect
• Feeling sick, anxious, or unable to sleep when doses are missed
• Trying to cut back and finding it harder than expected
• Spending more money on products than intended
• Using 7-OH alongside alcohol or other substances to amplify effects

Withdrawal from concentrated 7-OH can be as difficult as opioid withdrawal. That difficulty is one of the main reasons people are unable to stop on their own, even when they recognize the problem.

Buprenorphine/naloxone (Suboxone) is the FDA-approved medication used to treat opioid use disorder, including dependence on 7-OH. It stabilizes the opioid receptors that 7-OH acts on, preventing withdrawal and reducing cravings. It can be prescribed through a telehealth visit in most states, often within the same day someone reaches out.

Frequently Asked Questions

Are 7-OH tablets actually opioids?

Yes, pharmacologically. The FDA's 2025 scientific assessment describes 7-OH as a "novel potent opioid" that acts through mu-opioid receptor pathways consistent with classical opioids like morphine and fentanyl. The fact that it is derived from a plant does not change its pharmacological classification or its risks.

Did the FDA ban 7-OH tablets?

Not yet as of July 2026, though the regulatory picture is moving fast. The FDA issued warning letters to multiple companies in 2025 and recommended to the DEA that concentrated 7-OH be classified as Schedule I. In July 2026, the DEA filed notices of intent for temporary Schedule I placement; that order was expected to take effect no earlier than August 5, 2026. Several states have already enacted their own bans. Check current federal status before relying on this article for compliance decisions.

What is the difference between regular kratom and concentrated 7-OH tablets?

In the natural kratom leaf, 7-OH is present only in trace amounts. The dominant alkaloid, mitragynine, has lower opioid receptor affinity and, in animal research, a ceiling effect on respiratory depression. Concentrated 7-OH products remove both of those buffers. They deliver far higher 7-OH levels than the plant ever would, and the respiratory depression risk scales with dose without the same ceiling. The FDA specifically identified this distinction as the reason concentrated products are a separate and more serious risk category from kratom leaf.

Can you overdose on 7-OH tablets?

Yes. The FDA's adverse event data and county medical examiner reports both document fatal overdoses involving concentrated 7-OH, often alongside alcohol or sedatives. Signs of overdose include very slow or stopped breathing, unresponsiveness, blue lips or fingertips, and pinpoint pupils. Call 911 immediately and administer naloxone if available. Because 7-OH has a longer half-life than naloxone, repeat doses may be needed and hospital observation is important even after the person appears to wake up.

Is buprenorphine treatment available if I am dependent on 7-OH tablets?

Yes. Buprenorphine/naloxone (Suboxone) is the standard medication for opioid use disorder and is effective for 7-OH dependence because 7-OH acts through the same opioid receptors buprenorphine stabilizes. A telehealth provider can evaluate you by video and, if appropriate, send a prescription to your pharmacy the same day. Learn how Bicycle Health's treatment works.